<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00602199</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000582475</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC0375</secondary_id>
    <secondary_id>1439-04</secondary_id>
    <nct_id>NCT00602199</nct_id>
  </id_info>
  <brief_title>ABT-510 in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>A Phase II Study of Anti-angiogenesis Therapy for Metastatic Melanoma Using ABT-510</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <brief_summary>
    <textblock>
      RATIONALE: ABT-510 may stop the growth of melanoma by blocking blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving ABT-510 works in treating patients&#xD;
      with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Examine the safety profile of ABT-510 in patients with metastatic malignant melanoma.&#xD;
&#xD;
        -  Examine the antitumor activity (i.e., time to progression and response rates) in&#xD;
           patients treated with ABT-510.&#xD;
&#xD;
        -  Determine the pharmacodynamic effects of ABT-510 and its potential impact on immune cell&#xD;
           function in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive ABT-510 subcutaneously twice daily on days 1-21. Courses repeat&#xD;
      every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are obtained at baseline, before treatment on day 1 of cycles 2 and 3, and then&#xD;
      every other course thereafter for pharmacological and ancillary studies. Samples are&#xD;
      evaluated for EC enumeration, expression profiling, circulating tumor cell quantification,&#xD;
      analysis of T-cell functions (i.e., immunophenotyping for NK-, T- and B-cell phenotypes as&#xD;
      well as ELISPOT analysis against common environmental pathogens and T cell spectratyping),&#xD;
      and angiogenesis bioassays. Patients also undergo ultrasound-guided core tumor biopsies for&#xD;
      histological analysis of microvascular density (CD38 and von Willebrand Factor&#xD;
      immunohistochemistry) at baseline and before treatment on day 1 of courses 3 and 5.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for up to 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18-week progression-free survival rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate as defined by RECIST criteria</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of NK-cells, T-cells, and B-cells before the start of the first 5 courses of treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-510</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed malignant melanoma&#xD;
&#xD;
               -  Stage IV disease&#xD;
&#xD;
               -  No known potentially curative standard therapy that exists or is proven capable&#xD;
                  of extending life expectancy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No history of or current CNS metastases&#xD;
&#xD;
               -  MRI of the brain to confirm absence of CNS metastases within the past 28 days is&#xD;
                  required&#xD;
&#xD;
          -  No known, presently active carcinomatous meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 6 months&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3 times ULN&#xD;
&#xD;
          -  Creatinine ≤ 2.5 times ULN&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Prothrombin time normal&#xD;
&#xD;
          -  Willing to return to Mayo Clinic Rochester, Jacksonville or Scottsdale for follow-up&#xD;
&#xD;
          -  Must be able to self-administer or has a caregiver who can reliably administer&#xD;
             subcutaneous injections&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled or current infection&#xD;
&#xD;
          -  No New York Heart Association class III-IV heart disease&#xD;
&#xD;
          -  No recent history of (i.e., ≤ 12 weeks from study day 1) or current cancer-related&#xD;
             bleeding event (e.g., hemoptysis)&#xD;
&#xD;
          -  No recent history of (within the past 4 weeks) or current noncancer-related clinically&#xD;
             significant bleeding event&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No history of stroke or other CNS bleeding events (e.g., aneurysms)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered (6 weeks for mitomycin C or&#xD;
             nitrosoureas)&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy, biologic therapy, radiotherapy, or surgery&#xD;
&#xD;
          -  No concurrent anticoagulation therapy or antiplatelet therapy&#xD;
&#xD;
          -  No other concurrent antineoplastic agents (e.g., cytotoxic chemotherapy,&#xD;
             immunotherapy, radiotherapy, or investigational therapy) except local radiotherapy for&#xD;
             supportive reasons involving a small radiation field&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svetomir Markovic, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <results_reference>
    <citation>Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9.</citation>
    <PMID>17551310</PMID>
  </results_reference>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>January 11, 2008</study_first_submitted>
  <study_first_submitted_qc>January 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <last_update_submitted>May 13, 2011</last_update_submitted>
  <last_update_submitted_qc>May 13, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>Svetomir Nenad Markovic, M.D.</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

